CB-RAF600E-1 exerts efficacy in vemurafenib-resistant and non-resistant-melanoma cells via dual inhibition of RAS/RAF/MEK/ERK and PI3K/Akt signaling pathways

BACKGROUND AND AIM: Predicting novel dual inhibitors to combat adverse effects such as the development of resistance to vemurafenib in melanoma treatment due to the reactivation of MAPK and PI3K/AKT signaling pathways is studied to help in reversal of cancer symptoms. Reversal of cancer symptoms in...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Shahrani, Mesfer, Rajagopalan, Prasanna, Abohassan, Mohammad, Alshahrani, Mohammad, Alraey, Yasser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112009/
https://www.ncbi.nlm.nih.gov/pubmed/35592740
http://dx.doi.org/10.1016/j.sjbs.2022.103285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112009/
https://www.ncbi.nlm.nih.gov/pubmed/35592740
http://dx.doi.org/10.1016/j.sjbs.2022.103285

Ejemplares similares